ArticleThe Journal of pharmacology and experimental therapeutics2019
Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Pacemaking in the lymphatic system.The Journal of physiology · 2026Review
- Lymphatic pumping failure in the arm precedes dermal backflow and breast cancer-related lymphedema.Breast cancer research : BCR · 2026Article
- Article
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema.Microcirculation (New York, N.Y. : 1994) · 2025Review
- Aging-induced changes in lymphatic muscle cell transcriptomes are associated with reduced pumping of peripheral collecting lymphatic vessels in mice.Developmental cell · 2025Article
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Modelling pacemaker oscillations in lymphatic muscle cells: lengthened action potentials by two distinct system effects.Royal Society open science · 2025Article
- Current diagnostic and quantitative techniques in the field of lymphedema management: a critical review.Medical oncology (Northwood, London, England) · 2024Review
- Real-Time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels.Journal of visualized experiments : JoVE · 2024Article
- A dual-clock-driven model of lymphatic muscle cell pacemaking to emulate knock-out of Ano1 or IP3R.The Journal of general physiology · 2023Article
- IP3R1 underlies diastolic ANO1 activation and pressure-dependent chronotropy in lymphatic collecting vessels.The Journal of general physiology · 2023Article
- An integrative review of nonobvious puzzles of cellular and molecular cardiooncology.Cellular & molecular biology letters · 2023Review
- Lymphatic Clearance and Pump Function.Cold Spring Harbor perspectives in medicine · 2023Review
- Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells.International journal of molecular sciences · 2022Article
- Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging.Breast cancer research and treatment · 2022Observational
- Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy.Frontiers in oncology · 2022Article
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies.Frontiers in pharmacology · 2022Review
- Lymphatic Collecting Vessel: New Perspectives on Mechanisms of Contractile Regulation and Potential Lymphatic Contractile Pathways to Target in Obesity and Metabolic Diseases.Frontiers in pharmacology · 2022Review
- KThe Journal of pharmacology and experimental therapeutics · 2021Article
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Amanda J StolarzDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.) ajstolarz@uams.edu.
Mustafa SarimollaogluDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.).
John C MareckiDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.).
Terry W FletcherDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.).
Ekaterina I GalanzhaDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.).
Sung W RheeDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.).
Vladimir P ZharovDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.).
V Suzanne KlimbergDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.).
Nancy J RuschDepartment of Pharmacology and Toxicology, College of Medicine (A.J.S., T.W.F., S.W.R., N.J.R.) and Department of Biochemistry and Molecular Biology, College of Medicine (J.C.M.), Arkansas Nanomedicine Center, College of Medicine (M.S., V.P.Z.), Department of Pharmaceutical Sciences, College of Pharmacy (A.J.S.), and Laboratory of Lymphatic Research, Diagnosis and Therapy (E.I.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Division of Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, and MD Anderson Cancer Center Houston, Texas (V.S.K.).
University of Arkansas for Medical Sciences · US
Funding
The Role o f Tetrahydrobiopterin (BH4) Bioavailability in Radiation-induced Skin InjuryP20GM109005 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI BOERMA, MARJAN · 2015 to 2024
$21.1MIn vivo real-time detection of circulating melanoma cellsR01CA131164 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI SUEN, JAMES · 2009 to 2019
$3.1MPhotoswitchable nanoprobes for in vivo flow cytometryR01EB017217 · NIBIB · UNIV OF ARKANSAS FOR MED SCIS · PI ZHAROV, VLADIMIR P · 2014 to 2017
$1.3MInteraction of gold nanoparticles with lymphatic vesselsR21EB022698 · NIBIB · UNIV OF ARKANSAS FOR MED SCIS · PI GALANZHA, EKATERINA I. · 2016 to 2017
$398kDoxorubicin suppression of lymphatic function and therapeutic reversalR21CA187325 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI RUSCH, NANCY J · 2015 to 2016
$353kNCI NIH HHS R01 CA131164NCI NIH HHS R21 CA187325NIBIB NIH HHS R01 EB017217NIBIB NIH HHS R21 EB022698NIGMS NIH HHS P20 GM109005
Abstract
Doxorubicin is a risk factor for secondary lymphedema in cancer patients exposed to surgery or radiation. The risk is presumed to relate to its cytotoxicity. However, the present study provides initial evidence that doxorubicin directly inhibits lymph flow and this action appears distinct from its cytotoxic activity. We used real-time edge detection to track diameter changes in isolated rat mesenteric lymph vessels. Doxorubicin (0.5-20
Indexed as
AnimalsAntibiotics, AntineoplasticDose-Response Relationship, DrugDoxorubicinLymphLymphatic VesselsMaleMuscle CellsMuscle ContractionOrgan Culture TechniquesRatsRats, Sprague-DawleyRyanodine Receptor Calcium Release ChannelAntibiotics, AntineoplasticDoxorubicinRyanodine Receptor Calcium Release Channel
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.